Conservest Capital Advisors Inc. Purchases 3,782 Shares of VanEck Biotech ETF $BBH

Conservest Capital Advisors Inc. grew its position in VanEck Biotech ETF (NASDAQ:BBH) by 22.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,276 shares of the company’s stock after acquiring an additional 3,782 shares during the quarter. Conservest Capital Advisors Inc. owned about 1.03% of VanEck Biotech ETF worth $3,812,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Empowered Funds LLC purchased a new position in shares of VanEck Biotech ETF during the 4th quarter worth about $38,000. Flagship Harbor Advisors LLC bought a new position in VanEck Biotech ETF during the 4th quarter valued at about $47,000. Allworth Financial LP raised its position in VanEck Biotech ETF by 255.0% in the 4th quarter. Allworth Financial LP now owns 426 shares of the company’s stock worth $81,000 after purchasing an additional 306 shares during the period. Fifth Third Bancorp purchased a new stake in VanEck Biotech ETF in the 1st quarter worth about $127,000. Finally, Huntington National Bank bought a new stake in VanEck Biotech ETF in the fourth quarter worth about $132,000. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Performance

Shares of NASDAQ:BBH opened at $202.80 on Wednesday. VanEck Biotech ETF has a 1 year low of $154.75 and a 1 year high of $212.54. The business has a 50 day simple moving average of $191.96 and a two-hundred day simple moving average of $191.69.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.